Your browser doesn't support javascript.
loading
An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study.
Waldock, Joanna; Weiss, Carol D; Wang, Wei; Levine, Min Z; Jefferson, Stacie N; Ho, Sammy; Hoschler, Katja; Londt, Brandon Z; Masat, Elisa; Carolan, Louise; Sánchez-Ovando, Stephany; Fox, Annette; Watanabe, Shinji; Akimoto, Miki; Sato, Aya; Kishida, Noriko; Buys, Amelia; Maake, Lorens; Fourie, Cardia; Caillet, Catherine; Raynaud, Sandrine; Webby, Richard J; DeBeauchamp, Jennifer; Cox, Rebecca J; Lartey, Sarah L; Trombetta, Claudia M; Marchi, Serena; Montomoli, Emanuele; Sanz-Muñoz, Iván; Eiros, José María; Sánchez-Martínez, Javier; Duijsings, Danny; Engelhardt, Othmar G.
Affiliation
  • Waldock J; Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory, Potters Bar, United Kingdom.
  • Weiss CD; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
  • Wang W; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
  • Levine MZ; Influenza Division, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, United States.
  • Jefferson SN; Influenza Division, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, United States.
  • Ho S; Respiratory Viruses Unit, UK Health Security Agency, Colindale, United Kingdom.
  • Hoschler K; Respiratory Viruses Unit, UK Health Security Agency, Colindale, United Kingdom.
  • Londt BZ; hVivo The Queen Mary Bioenterprises (QMB) Innovation, London, United Kingdom.
  • Masat E; hVivo The Queen Mary Bioenterprises (QMB) Innovation, London, United Kingdom.
  • Carolan L; World Health Organisation (WHO) Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Sánchez-Ovando S; World Health Organisation (WHO) Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Fox A; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Watanabe S; World Health Organisation (WHO) Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Akimoto M; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Sato A; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases: Musashi-Murayama, Tokyo, Japan.
  • Kishida N; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases: Musashi-Murayama, Tokyo, Japan.
  • Buys A; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases: Musashi-Murayama, Tokyo, Japan.
  • Maake L; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases: Musashi-Murayama, Tokyo, Japan.
  • Fourie C; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Services, Johannesburg, South Africa.
  • Caillet C; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Services, Johannesburg, South Africa.
  • Raynaud S; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Services, Johannesburg, South Africa.
  • Webby RJ; Department of Research and Development, Sanofi, Lyon, France.
  • DeBeauchamp J; Department of Research and Development, Sanofi, Lyon, France.
  • Cox RJ; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, United States.
  • Lartey SL; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, United States.
  • Trombetta CM; Influenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
  • Marchi S; Influenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
  • Montomoli E; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
  • Sanz-Muñoz I; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
  • Eiros JM; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
  • Sánchez-Martínez J; National Influenza Centre of Valladolid, Instituto de Estudios de Ciencias de la Salud de Castilla y León (ICSCYL), Edificio Rondilla, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Duijsings D; National Influenza Centre of Valladolid, Instituto de Estudios de Ciencias de la Salud de Castilla y León (ICSCYL), Edificio Rondilla, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Engelhardt OG; National Influenza Centre of Valladolid, Instituto de Estudios de Ciencias de la Salud de Castilla y León (ICSCYL), Edificio Rondilla, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Front Immunol ; 14: 1129765, 2023.
Article in En | MEDLINE | ID: mdl-36926342
ABSTRACT

Introduction:

External Quality Assessment (EQA) schemes are designed to provide a snapshot of laboratory proficiency, identifying issues and providing feedback to improve laboratory performance and inter-laboratory agreement in testing. Currently there are no international EQA schemes for seasonal influenza serology testing. Here we present a feasibility study for conducting an EQA scheme for influenza serology methods.

Methods:

We invited participant laboratories from industry, contract research organizations (CROs), academia and public health institutions who regularly conduct hemagglutination inhibition (HAI) and microneutralization (MN) assays and have an interest in serology standardization. In total 16 laboratories returned data including 19 data sets for HAI assays and 9 data sets for MN assays.

Results:

Within run analysis demonstrated good laboratory performance for HAI, with intrinsically higher levels of intra-assay variation for MN assays. Between run analysis showed laboratory and strain specific issues, particularly with B strains for HAI, whilst MN testing was consistently good across labs and strains. Inter-laboratory variability was higher for MN assays than HAI, however both assays showed a significant reduction in inter-laboratory variation when a human sera pool is used as a standard for normalization.

Discussion:

This study has received positive feedback from participants, highlighting the benefit such an EQA scheme would have on improving laboratory performance, reducing inter laboratory variation and raising awareness of both harmonized protocol use and the benefit of biological standards for seasonal influenza serology testing.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza, Human Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza, Human Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: United kingdom